Company Name
89bio Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US2825591033
CIK:
0001785173
CUSIP:
282559103
Currency:
USD
Full Time Employees:
93
Phone:
415 432 9270
Website:
https://www.89bio.com
Fiscal Year End:
December
IPO Date:
Nov 11, 2019
Description:
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly known as The company was founded in 2018 and is based in San Francisco, California. As of October 29, 2025, 89bio, Inc. operates as a subsidiary of Roche Holding AG.
Address:
655 Montgomery Street, San Francisco, CA, United States, 94111